Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients

Journal of Affective Disorders

Volumn 113, Issue 1-2, 2009, Pages 183-187

  Tsai, Shih Jen ^a,b   Gau, Yung Tian A ^b   Hong, Chen Jee ^a,b   Liou, Ying Jay ^a,b,c   Yu, Younger W Y ^d   Chen, Tai Jui ^e  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d Yu's Psychiatric Clinic   (Taiwan)

^e I SHOU UNIVERSITY   (Taiwan)

Author keywords

Catechol O methyltransferase; Fluoxetine; Major depressive disorder; Pharmacogenetics; Polymorphisms

Indexed keywords

CATECHOL METHYLTRANSFERASE; FLUOXETINE; METHIONINE; PLACEBO; VALINE;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG DOSE INCREASE; ENZYME POLYMORPHISM; FEMALE; GENDER; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT RESPONSE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; FLUOXETINE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; SEX FACTORS;

EID: 58149097604     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2008.04.017     Document Type: Article

References (37)

1. Arias B., Serretti A., Lorenzi C., Gastó C., Catalán R., and Fañanás L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J. Affect. Disord. 90 (2006) 251-256
2. Asberg M., and Mårtensson B. Serotonin selective antidepressant drugs: past, present, future. Clin. Neuropharmacol. 16 Suppl 3 (1993) S32-S44
3. Barnett J.H., Heron J., Ring S.M., Golding J., Goldman D., Xu K., et al. Gender-specific effects of the catechol-O-methyltransferase Val108/158Met polymorphism on cognitive function in children. Am. J. Psychiatry 164 (2007) 142-149
4. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33 (2008) 924-932
5. Burke W.J., Hendricks S.E., McArthur-Campbell D., Jacques D., and Stull T. Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacol. Bull. 32 (1996) 27-32
6. 3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse 10 (1992) 264-266
7. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75 (2004) 807-821
8. Davidson R.T., Mcleod M.N., White H.L., and Raft D. Red blood cell catechol O-methyl transferase and response to imipramine in unipolar depressive women. Am. J. Psychiatry 133 (1976) 952-955
9. Detera-Wadleigh S.D., and McMahon F.J. Genetic association studies in mood disorders: issues and promise. Int. Rev. Psychiatry 16 (2004) 301-310
10. 2C receptors in the control of central dopamine function. Trends. Pharmacol. Sci. 22 (2001) 229-232
11. Dunlop B.W., and Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 64 (2007) 327-337
12. Fava M. Management of nonresponse and intolerance: switching strategies. J. Clin. Psychiatry 61 Suppl 2 (2000) 10-12
13. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., and Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 48 (1991) 851-855
14. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9991-9996
15. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6 (1967) 278-296
16. Harrison P.J., and Tunbridge E.M. Catechol-O-Methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology (2007) 10.1038/sj.npp.1301543
17. Huotari M., Gogos J.A., Karayiorgou M., Koponen O., Forsberg M., Raasmaja A., et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur. J. Neurosci. 15 (2002) 246-256
18. Jiang H., Xie T., Ramsden D.B., and Ho S.L. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology 45 (2003) 1011-1018
19. Kia-Keating B.M., Glatt S.J., and Tsuang M.T. Meta-analyses suggest association between COMT, but not HTR1B, alleles, and suicidal behavior. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 1048-1053
20. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
21. Leo R.J. Movement disorders associated with the serotonin selective reuptake inhibitors. J. Clin. Psychiatry 57 (1996) 449-454
22. Li T., Chen C.K., Hu X., Ball D., Lin S.K., Chen W., et al. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129 (2004) 120-124
23. Männistö P.T., and Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 51 (1999) 593-628
24. Naranjo C.A., Tremblay L.K., and Busto U.E. The role of the brain reward system in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 25 (2001) 781-823
25. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 9 (2006) 1151-1159
26. Parsons L.H., Weiss F., and Koob G.F. Serotonin1b receptor stimulation enhances dopamine-mediated reinforcement. Psychopharmacology 128 (1996) 150-160
27. Philippu G., Hoo J.J., Milech U., Argarwall D.P., Schrappe O., and Goedde H.W. Catechol-O-methyltransferase of erythrocytes in patients with endogenous psychoses. Psychiatry Res. 4 (1981) 139-146
28. Plaznik A., and Kostowski W. The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system: a behavioral study. Eur. J. Pharmacol. 135 (1987) 389-396
29. Pooley E.C., Fineberg N., and Harrison P.J. The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis. Mol. Psychiatry 12 (2007) 556-561
30. Prisco S., and Esposito E. Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmacol. 116 (1995) 1923-1931
31. Puzynski S., Bidzinski A., Mrozek S., and Zaluska M. Studies on biogenic amine metabolizing enzymes (DBH, COMT, MAO) and pathogenesis of affective illness. II. Erythrocyte catechol-O-methyltransferase activity in endogenous depression. Acta Psychiatr. Scand. 67 (1983) 96-100
32. Rush A.J., Kraemer H.C., Sackeim H.A., Fava M., Trivedi M.H., Frank E., et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31 (2006) 1841-1853
33. Serretti A., Artioli P., and Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet. Genomics 15 (2005) 61-67
34. Sham P.C., and Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59 (1995) 97-105
35. Szegedi A., Rujescu D., Tadic A., Müller M.J., Kohnen R., Stassen H.H., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 5 (2005) 49-53
36. West A.R., and Galloway M.P. Regulation of serotonin-facilitated dopamine release in vivo: the role of protein kinase A activating transduction mechanisms. Synapse 23 (1996) 20-27
37. Xie T., Ho S.L., and Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol. Pharmacol. 56 (1999) 31-38